The latest price target for Tharimmune (NASDAQ:THAR) was reported by Rodman & Renshaw on December 6, 2024. The analyst firm set a price target for $17.00 expecting THAR to rise to within 12 months (a possible 729.27% upside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for Tharimmune (NASDAQ:THAR) was provided by Rodman & Renshaw, and Tharimmune initiated their buy rating.

There is no last upgrade for Tharimmune

There is no last downgrade for Tharimmune.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Tharimmune, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Tharimmune was filed on December 6, 2024 so you should expect the next rating to be made available sometime around December 6, 2025.

While ratings are subjective and will change, the latest Tharimmune (THAR) rating was a initiated with a price target of $0.00 to $17.00. The current price Tharimmune (THAR) is trading at is $2.05, which is within the analyst’s predicted range.